Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Cash Flows [Abstract]
Net income (loss)	$ (22,054)	$ 4,576
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Provision for (recovery of) bad debts	145	(535)
Deferred tax benefit (expense)	6,649	(109)
Depreciation and amortization	23,023	6,481
Amortization of debt discount and issuance costs	1,710	3,586
Equity-based compensation	4,508	7,911
Contingent consideration	(3,731)	148
Warranty provision	594	302
Provision for inventory obsolescence	409	0
Changes in operating assets and liabilities, net of business acquisition
Accounts receivable	(44,268)	(5,000)
Inventories	(46,250)	(6,246)
Income tax receivables	(21,924)	13,003
Prepaid expenses and other	5,960	(3,216)
Accounts payable	59,551	(10,556)
Accounts payable - related party	(132)	0
Accrued expenses and other	7,027	5,134
Income tax payable	(8,760)	2,067
Lease liabilities	6,085	247
Deferred revenue	(18,639)	(59,941)
Net cash used in operating activities	(50,097)	(42,148)
Cash flows from investing activities
Purchase of property, plant and equipment	(2,357)	(570)
Acquisition of STI, net of cash acquired	(373,816)	0
Investment in equity security	0	(10,000)
Net cash used in investing activities	(376,173)	(10,570)
Cash flows from financing activities
Proceeds from Series A issuance	33,098	0
Proceeds from common stock issuance	15,885	0
Series A equity issuance costs	175	0
Common stock issuance costs	(450)	0
Proceeds from revolving credit facility	52,000	0
Proceeds from issuance of other debt	6,229	0
Principal payments on debt	(4,368)	(30,000)
Contingent consideration	(1,483)	0
Debt issuance costs	0	6,590
Net cash provided by (used in) financing activities	100,736	(36,590)
Effect of exchange rate changes on cash and cash equivalent balances	7,355	0
Net change in cash and cash equivalents	(318,179)	(89,308)
Cash and cash equivalents, beginning of period	367,670	108,441
Cash and cash equivalents, end of period	49,491	19,133
Supplemental Cash Flow Information
Stock consideration paid for acquisition of STI	$ 200,224	$ 0